155 related articles for article (PubMed ID: 11093361)
1. Marimastat: the clinical development of a matrix metalloproteinase inhibitor.
Steward WP; Thomas AL
Expert Opin Investig Drugs; 2000 Dec; 9(12):2913-22. PubMed ID: 11093361
[TBL] [Abstract][Full Text] [Related]
2. Marimastat (BB2516): current status of development.
Steward WP
Cancer Chemother Pharmacol; 1999; 43 Suppl():S56-60. PubMed ID: 10357560
[TBL] [Abstract][Full Text] [Related]
3. Marimastat: BB 2516, TA 2516.
Drugs R D; 2003; 4(3):198-203. PubMed ID: 12757409
[TBL] [Abstract][Full Text] [Related]
4. Development of matrix metalloproteinase inhibitors in cancer therapy.
Hidalgo M; Eckhardt SG
J Natl Cancer Inst; 2001 Feb; 93(3):178-93. PubMed ID: 11158186
[TBL] [Abstract][Full Text] [Related]
5. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.
Shepherd FA; Giaccone G; Seymour L; Debruyne C; Bezjak A; Hirsh V; Smylie M; Rubin S; Martins H; Lamont A; Krzakowski M; Sadura A; Zee B
J Clin Oncol; 2002 Nov; 20(22):4434-9. PubMed ID: 12431965
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer.
Miller KD; Gradishar W; Schuchter L; Sparano JA; Cobleigh M; Robert N; Rasmussen H; Sledge GW
Ann Oncol; 2002 Aug; 13(8):1220-4. PubMed ID: 12181245
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Goffin JR; Anderson IC; Supko JG; Eder JP; Shapiro GI; Lynch TJ; Shipp M; Johnson BE; Skarin AT
Clin Cancer Res; 2005 May; 11(9):3417-24. PubMed ID: 15867243
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice.
Kimata M; Otani Y; Kubota T; Igarashi N; Yokoyama T; Wada N; Yoshimizu N; Fujii M; Kameyama K; Okada Y; Kumai K; Kitajima M
Jpn J Cancer Res; 2002 Jul; 93(7):834-41. PubMed ID: 12149150
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA.
Watson SA; Morris TM; Collins HM; Bawden LJ; Hawkins K; Bone EA
Br J Cancer; 1999 Sep; 81(1):19-23. PubMed ID: 10487607
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cervical lymph node metastasis by marimastat (BB-2516) in an orthotopic oral squamous cell carcinoma implantation model.
Maekawa K; Sato H; Furukawa M; Yoshizaki T
Clin Exp Metastasis; 2002; 19(6):513-8. PubMed ID: 12405288
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.
Wojtowicz-Praga S; Torri J; Johnson M; Steen V; Marshall J; Ness E; Dickson R; Sale M; Rasmussen HS; Chiodo TA; Hawkins MJ
J Clin Oncol; 1998 Jun; 16(6):2150-6. PubMed ID: 9626215
[TBL] [Abstract][Full Text] [Related]
12. Ongoing trials with matrix metalloproteinase inhibitors.
Brown PD
Expert Opin Investig Drugs; 2000 Sep; 9(9):2167-77. PubMed ID: 11060801
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy.
Toppmeyer DL; Gounder M; Much J; Musanti R; Vyas V; Medina M; Orlando T; Pennick M; Lin Y; Shih W; Goodin S; Rubin E
Med Sci Monit; 2003 Aug; 9(8):PI99-104. PubMed ID: 12942041
[TBL] [Abstract][Full Text] [Related]
14. Marimastat in patients with advanced pancreatic cancer: a dose-finding study.
Rosemurgy A; Harris J; Langleben A; Casper E; Goode S; Rasmussen H
Am J Clin Oncol; 1999 Jun; 22(3):247-52. PubMed ID: 10362330
[TBL] [Abstract][Full Text] [Related]
15. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects.
King J; Zhao J; Clingan P; Morris D
Anticancer Res; 2003; 23(1B):639-45. PubMed ID: 12680160
[TBL] [Abstract][Full Text] [Related]
16. The interaction of metal ions and Marimastat with matrix metalloproteinase 9.
Underwood CK; Min D; Lyons JG; Hambley TW
J Inorg Biochem; 2003 Jun; 95(2-3):165-70. PubMed ID: 12763661
[TBL] [Abstract][Full Text] [Related]
17. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial.
Bramhall SR; Hallissey MT; Whiting J; Scholefield J; Tierney G; Stuart RC; Hawkins RE; McCulloch P; Maughan T; Brown PD; Baillet M; Fielding JW
Br J Cancer; 2002 Jun; 86(12):1864-70. PubMed ID: 12085177
[TBL] [Abstract][Full Text] [Related]
18. Is British Biotech's Marimastat a major cancer drug?
Davidson S
Nat Biotechnol; 1996 Jul; 14(7):819-20. PubMed ID: 9630998
[No Abstract] [Full Text] [Related]
19. A phase II trial of marimastat in advanced pancreatic cancer.
Evans JD; Stark A; Johnson CD; Daniel F; Carmichael J; Buckels J; Imrie CW; Brown P; Neoptolemos JP
Br J Cancer; 2001 Dec; 85(12):1865-70. PubMed ID: 11747327
[TBL] [Abstract][Full Text] [Related]
20. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen.
Primrose JN; Bleiberg H; Daniel F; Van Belle S; Mansi JL; Seymour M; Johnson PW; Neoptolemos JP; Baillet M; Barker K; Berrington A; Brown PD; Millar AW; Lynch KP
Br J Cancer; 1999 Feb; 79(3-4):509-14. PubMed ID: 10027321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
